ES2181054T3 - Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento. - Google Patents

Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.

Info

Publication number
ES2181054T3
ES2181054T3 ES97953157T ES97953157T ES2181054T3 ES 2181054 T3 ES2181054 T3 ES 2181054T3 ES 97953157 T ES97953157 T ES 97953157T ES 97953157 T ES97953157 T ES 97953157T ES 2181054 T3 ES2181054 T3 ES 2181054T3
Authority
ES
Spain
Prior art keywords
product
protein product
glp
kgf
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97953157T
Other languages
English (en)
Inventor
Catherine L Farrell
Yue-Sheng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2181054T3 publication Critical patent/ES2181054T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

El uso de uno o varios productos proteicos de KGF y uno o varios productos proteicos de GLP-2 para la preparación de un medicamento para incrementar la citoprotección, la proliferación y/o la diferenciación de las células epiteliales en el tracto gastrointestinal de un paciente.
ES97953157T 1996-12-06 1997-12-08 Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento. Expired - Lifetime ES2181054T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3253396P 1996-12-06 1996-12-06
US6207497P 1997-10-15 1997-10-15

Publications (1)

Publication Number Publication Date
ES2181054T3 true ES2181054T3 (es) 2003-02-16

Family

ID=26708564

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97953157T Expired - Lifetime ES2181054T3 (es) 1996-12-06 1997-12-08 Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.

Country Status (10)

Country Link
EP (1) EP1012186B1 (es)
JP (1) JP4091988B2 (es)
AT (1) ATE220689T1 (es)
AU (1) AU5696298A (es)
CA (1) CA2272854C (es)
DE (1) DE69714085T2 (es)
DK (1) DK1012186T3 (es)
ES (1) ES2181054T3 (es)
PT (1) PT1012186E (es)
WO (1) WO1998024813A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
DK0981362T3 (da) * 1997-05-16 2004-03-15 Ontario Inc 1149336 Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
ATE396202T1 (de) * 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
JP2005500390A (ja) 2001-08-21 2005-01-06 カイロン コーポレイション Ｋｇｆポリペプチド組成物
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
US8304387B2 (en) * 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
WO2015063613A2 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
ES2909074T3 (es) * 2016-05-06 2022-05-05 Phasebio Pharmaceuticals Inc Proteínas de fusión ELP para liberación controlada y sostenida

Also Published As

Publication number Publication date
WO1998024813A3 (en) 1998-08-06
EP1012186B1 (en) 2002-07-17
ATE220689T1 (de) 2002-08-15
CA2272854C (en) 2004-02-10
CA2272854A1 (en) 1998-06-11
AU5696298A (en) 1998-06-29
DE69714085D1 (de) 2002-08-22
WO1998024813A2 (en) 1998-06-11
JP2001510333A (ja) 2001-07-31
DE69714085T2 (de) 2002-11-14
EP1012186A2 (en) 2000-06-28
DK1012186T3 (da) 2002-11-04
JP4091988B2 (ja) 2008-05-28
PT1012186E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
MX22877A (es) Procedimiento para la preparacion de pirimidas, producto obtenido y composicion farmaceutica que lo incluye
EP2258402A3 (en) Dried composition
LV12438A (en) Metode of preventing and delyaing the onset of alzheimer's disease and composition thereof
EP0973540A4 (en) INSULATION AND STRUCTURAL ENLARGEMENT OF THE CRYOSTATIC LINEAR AND CYCLO DEPSIPEPTIDE DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18
AU6245098A (en) Marking of products to extablish identity, source and fate
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ES2181054T3 (es) Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
ES2162929T3 (es) Procedimiento para la preparacion de 2-(1-azabiciclo(2.2.2)oct-3-il)-2,4,5,6-tetrahidro-1h-benz(de)isoquinolin-1-ona y producto intermediario.
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
MX14310A (es) Procedimiento para la preparacion de nuevos agentes antiarritmicos, producto obtenido y preparacion farmaceutica que lo incluye.
AU4926690A (en) Oxidized diphenylheteroalkanes, the preparation and use thereof
EP0844017A4 (en) PROCESS FOR PRODUCING AN EMULGATOR AND EMULSIFIED COMPOSITION
DK0443848T3 (da) Nyt antiulcermiddel
MX17107A (es) Procedimiento para la preparacion de tiazolo-(1,5)-benzodiazepinas y producto obtenido
AU8235291A (en) Lyophilized native collagen sheets comprising cosmetic formulations for the treatment of couperose
ES2051916T3 (es) Procedimiento para la obtencion de formiltrimetilbiciclo(2.2.2)oct-7-enos isomeros.
EP0897988A4 (en) TKR1785'S PHYSIOLOGICALLY ACTIVE SUBSTANCES, THEIR PROCESS AND MICROBE
DE59610341D1 (de) Verfahren zur Herstellung von 2,4,6-Trichlorpyrimidin
DE69534740D1 (en) Analoge des thymosin alpha 1
MX23342A (es) Procedimiento para la preparacion de compuestos azabiciclicos, producto obtenido y composicion farmaceutica que lo incluye.
MX14871A (es) Procedimiento para la preparacion de pirroles substituidos y producto obtenido.
SI1012186T1 (en) Use of a kgf protein product(s) and a glp-2 protein product(s) for the preparation of a medicament
MX20574A (es) Procedimiento para la preparacion de derivados de la sacarina y producto obtenido.
ECSP961970A (es) DEHIDRATO DE (2R,3S)-3- TERI - BUTOXICARBONILAMINO -2- HIDROXI - 3- FENILPROPIONATO DE 4,10ß- DIACETOXI-2ALFA- BENZOILOXI - 5ß, 20- EPOXI - 1- HIDROXI - 9- OXO - 19 - NORCICLOPROPA [G] TAX - 11 - ENE - 13ALFA - ILE Y SU PROCEDIMIENTO DE PREPARACION